Last updated: July 14, 2026
The 24–48-hour Holter monitor has been the default ambulatory ECG tool for decades. Its brief recording window is structurally mismatched to the episodic nature of most clinically significant arrhythmias. A 24-hour Holter captures events in a limited number of patients with intermittent arrhythmias, while extended adhesive patch monitoring achieves higher diagnostic yields.
The gap widens for specific arrhythmia subtypes. A substantial share of sustained ventricular tachycardia events are first detected after the initial 48 hours of monitoring. In post-ablation surveillance, some patients have their first detected AF recurrence beyond 48 hours, events a standard Holter would classify as false negatives. Short-term monitoring can miss AF recurrences following PVI.
The consequence is a cycle of repeat testing, delayed diagnosis, and deferred treatment that raises both clinical risk and administrative cost. A retrospective analysis of 287,780 Medicare beneficiaries confirmed that 14-day patch monitoring delivered the highest initial diagnostic yield and the lowest odds of retesting within 6 months, compared with Holter, event monitors, and mobile cardiac telemetry.
Clinical guidelines from the ACC/AHA/HRS and the Heart Rhythm Society converge on one principle. Clinicians should choose a monitor based on symptom frequency and patient preferences. The framework below maps symptom cadence to the evidence-supported modality.
Each step up in monitoring duration corresponds to a measurable rise in billable diagnostic events. That connects clinical appropriateness directly to practice revenue, and it also raises a separate operational question: how does a clinic manage data from all these different devices at once?
Picking the right device is a clinical decision. Managing the data that flows from it, alongside data from pacemakers, ICDs, CRT devices, CardioMEMS sensors, and chronic-condition RPM hardware, is an operational one. Rhythm360 addresses the operational layer by ingesting and normalizing data from all major OEMs, including Medtronic, Boston Scientific, Abbott, and Biotronik, into a single vendor-neutral dashboard.
Key platform capabilities include:
Ready to consolidate your OEM data streams into one view? Talk to the Rhythm360 team.
A clinic managing devices from three or more OEMs typically needs staff to maintain separate logins, learn separate interfaces, and reconcile data from portals that don't talk to each other. Device clinics process a large volume of transmissions annually, and many generate clinically non-relevant alerts. That volume drives the conditioned inattention that clinical researchers identify as the most dangerous manifestation of alarm fatigue, directly implicated in delayed responses to life-threatening arrhythmias.
Rhythm360 replaces that fragmented workflow with a single login and a prioritized alert queue. The platform's AI triage layer distinguishes clinically significant events, such as new-onset AF, ventricular tachycardia, lead malfunction, and ERI/RRT indicators, from non-actionable transmissions before they reach clinical staff. Marcus Pritchett, Cardiac Device Specialist at Kansas City Heart Rhythm Institute, put it this way: "Having alert systems clear urgent versus non-urgent is the timeline difference." This triage layer is what allows Rhythm360 to compress response times across adopting clinics.
Revenue leakage in cardiac monitoring is mostly a documentation problem. When staff don't capture billable events in a CPT-compliant format at the time of transmission review, claims get delayed, rejected, or never submitted at all. Rhythm360 closes that gap by generating auditable documentation at the point of clinical review, supporting the full range of relevant codes:
The financial impact shows up at scale. University of Chicago Medicine reviewed more than 73,000 reports annually through Rhythm360 in calendar year 2025, averaging more than 18,000 reports per quarter. Gaurav A. Upadhyay, MD, at UCM, said: "We have improved billing and accountability for our patients after the integration." Across adopting practices, Rhythm360 has supported a documented 300% increase in revenue generation through better CPT code capture and improved staff efficiency.
Rhythm360's onboarding process minimizes disruption to active clinical workflows. Teams configure bi-directional EHR integration with Epic, Cerner, Athenahealth, eClinicalWorks, and Greenway Health during implementation, so data flows automatically from day one. The SaaS pricing model scales with clinic size and platform usage, with no rigid setup fees that penalize smaller practices or early-stage RPM programs.
Andrew Beaser, MD, Associate Professor of Medicine at University of Chicago Medicine, described the clinical impact of the switch: "We are able to address these issues earlier; rather than waiting for a 3-month visit, we can call patients in for evaluation." He added that "decision support, including AI-assisted decision support, will become increasingly important as data volumes grow."
No single device replaced the Holter monitor. Instead, a spectrum of modalities now gets matched to symptom frequency. Extended-wear adhesive patches worn for 7–14 days are the most common alternative for patients with weekly or less-frequent symptoms, offering continuous single-lead ECG recording without lead wires. Mobile cardiac outpatient telemetry (MCOT) provides 30-day continuous monitoring with real-time wireless transmission, making it appropriate for higher-risk patients or those with symptoms that may not be perceptible. Implantable loop recorders (ILRs) are subcutaneously implanted devices that monitor continuously for up to three years, reserved for patients with infrequent, unexplained symptoms after external monitoring comes back nondiagnostic. The 24–48-hour Holter still fits patients with daily or near-daily symptoms, where the odds of capturing an event within the window stay high.
For patients with symptoms occurring less than daily, the evidence favors extended-wear patch monitoring over the standard 24–48-hour Holter. In a study of 146 patients undergoing simultaneous 24-hour Holter and 14-day patch monitoring, the patch detected 96 arrhythmias compared with 61 detected by Holter. Among 26,751 first-time patch users, at least one arrhythmia showed up in 60.3% of patients, and 29.9% of first arrhythmias were detected only after the initial 48 hours. As noted earlier, the large Medicare retrospective analysis found 14-day patch monitoring outperformed other modalities on both diagnostic yield and retesting rates. For patients with daily symptoms, though, the 24–48-hour Holter remains a clinically appropriate and cost-effective first step. The right choice depends on symptom frequency, patient compliance, and the clinical question being asked, not a universal ranking of one device over another.
Alert fatigue in multi-OEM environments comes from two compounding sources: the volume of non-actionable transmissions from any single device type, and the added burden of logging into separate portals for each manufacturer. Studies consistently find that only 10–20% of clinical alarms require intervention, and a typical device clinic processes over 8,000 transmissions annually, with nearly 60% of alerts clinically non-relevant. The most effective fix is consolidating all OEM data streams into a single platform with an AI-powered triage layer that filters non-actionable alerts before they reach clinical staff. Rhythm360 uses this approach to surface only prioritized, clinically significant events and route them to the right clinician via mobile notification. Optional 24/7 oversight by certified cardiac technicians adds another triage layer for practices that need continuous coverage without expanding in-house headcount.
The applicable codes depend on device type and the service being billed. For cardiac implantable electronic devices, remote interrogation falls under codes in the 93731–93743 range depending on device type, with 93298 covering remote data acquisition for pacemakers and ICDs. For remote physiological monitoring of chronic conditions such as heart failure or hypertension, the primary codes are 99453 (initial device setup and patient education), 99454 (device supply with data transmission for 16 or more days in a 30-day period), 99457 (first 20 minutes per month of treatment management), and 99458 (each additional 20 minutes beyond the initial 20). A 2026 CMS Final Physician Fee Schedule update added codes 99445 and 99470 to cover scenarios with fewer than 16 days of data transmission or fewer than 20 minutes of interactive communication per month. Only one practitioner may bill RPM services per patient in any 30-day period, and RPM can't be billed concurrently with remote therapeutic monitoring for the same patient. Rhythm360 automates documentation for all of these codes, generating CPT-compliant reports at the point of clinical review to reduce claim rejections and capture previously missed billable events.
The clinical case for extended arrhythmia monitoring is settled. Patch monitors, MCOT, and ILRs each deliver diagnostic yields that a 24–48-hour Holter can't match for intermittent presentations. Guidelines from the ACC/AHA/HRS, Heart Rhythm Society, and ESC give clinicians a clear symptom-frequency framework for choosing among them.
The operational case for a unified platform is just as clear. Clinics managing data from multiple OEMs without a centralized system face administrative overload, alert fatigue, and revenue leakage that no single device upgrade can resolve. Rhythm360 provides the infrastructure that makes modern monitoring operationally sustainable: one dashboard, AI-powered triage, automated CPT documentation, and bi-directional EHR integration that goes live in days. The results documented at University of Chicago Medicine and across adopting practices show the measurable return on replacing fragmented workflows with a single source of truth.
See Rhythm360 in action. Schedule a walkthrough tailored to your clinic's device mix.
